THNR

NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Dollar change -0.25
Percentage change -1.13	%

Category	Global or ExUS Equities - Industry Sector	Asset Type	Equities (Stocks)	Tags	Global	Return% 1Y	-12.74%	Shs Outstand		Perf Week	-0.59%
Sponsor	Amplify Investments	ETF Type		Tags	equity	Return% 3Y	-	Total Holdings	27	Perf Month	5.85%
Fund Family		Bond Type		Tags	healthcare	Return% 5Y	-	AUM	2.86M	Perf Quarter	-4.84%
Index	VettaFi Weight Loss Drug & Treatment Ind...	Average Maturity		Tags	pharmaceutical	Return% 10Y		NAV%		Perf Half Y	-8.88%
Index Weighting		Commodity Type		Tags	-	Return% SI		NAV/sh		Perf Year	-
Active/Passive		Quant Type		Tags	-	Flows% 1M	-13.45%	52W Range	18.56 - 28.19	Perf YTD	-3.24%
Dividend TTM	0.22 (1.01%)	ESG Type		Tags	-	Flows% 3M	-26.84%	52W High	-22.61%	Beta	0.60
Dividend Ex-Date	Dec 30, 2024	Dividend Type		Sector/Theme		Flows% YTD	-26.84%	52W Low	17.56%	ATR (14)	0.39
Expense	0.59%	Structure Type		Region		Flows% 1Y		RSI (14)	53.88	Volatility	1.90% 1.61%
Option/Short	No / Yes	Growth/Value		Dev/Emerg		Flows% 3Y		Rel Volume	3.98	Prev Close	22.07
Inverse/Leveraged		Market Cap		Currency		Flows% 5Y		Avg Volume	1.78K	Price	21.82
SMA20	0.60%	SMA50	2.08%	SMA200	-8.96%	Trades		Volume	7,072	Change	-1.13%

May-15-25 10:00AM	ETFs to Capitalize on the Novo Nordisk-Septerna Deal (Zacks)
Jan-16-25 07:00AM	Amplify ETFs Achieves Landmark $10 Billion in Assets Under Management (GlobeNewswire)
Sep-04-24 12:26PM	3 ETFs to stabilize a portfolio amid volatility: Amplify CEO (Yahoo Finance Video)
Jun-05-24 07:00AM	Amplify ETFs Earns Four Nominations for With Intelligence Mutual Fund and ETF Awards (GlobeNewswire)
May-21-24 07:00AM	Amplify ETFs Launches The Amplify Weight Loss Drug & Treatment ETF (THNR) (GlobeNewswire)

Amplify Weight Loss Drug & Treatment ETF seeks investment results that generally correspond to the performance (before fees and expenses) of the VettaFi Weight Loss Drug & Treatment Index. The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies who are manufacturers in the GLP-1 agonist pharmaceutical business or who enable such business. GLP-1 agonists (glucagon-like peptide) seek to lower blood sugar levels and reduce appetite and promote fullness, with the ultimate potential for weight loss. The fund is non-diversified.

open in yahoo | open in marketwatch | open in google

Amplify Weight Loss Drug & Treatment ETF

Upgrade your FINVIZ experience